Insulin-like growth factor-1 cytokines cross-talk in type 1 diabetes mellitus: Relationship to microvascular complications and bone mineral density

Cytokine

Volumn 59, Issue 1, 2012, Pages 86-93

  AboElAsrar, Mohammed A ^a   Elbarbary, Nancy S ^a   Elshennawy, Dina E ^a   Omar, Amin M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bone mineral density; Insulin like growth factor 1; Interleukin 6; Interleukin 8; Type 1 diabetes

Indexed keywords

CYTOKINE; HEMOGLOBIN A1C; INSULIN GLARGINE; INTERLEUKIN 6; INTERLEUKIN 8; ISOPHANE INSULIN; SHORT ACTING INSULIN; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EGYPT; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MICROANGIOPATHY; MOLECULAR INTERACTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ADOLESCENT; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICROVESSELS;

EID: 84861731700     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.03.019     Document Type: Article

References (71)

1. Leger J., Marinovic D., Alberti C., Dorgeret S., Chevenne D., Marchal C., et al. Lower bone mineral content in children with type 1 diabetes mellitus is linked to female sex, low insulin-like growth factor type1 levels, and high insulin requirement. J Clin Endocrionl Metab 2006, 91:3947-3953.
2. Niu T., Rosen C.J. The insulin-like growth factor-1 gene and osteoporosis: a critical appraisal. Gene 2005, 361:38-56.
3. Frystyk J., Ritzel R.A., Maubach J., Büsing M., Lück R., Klempnauer J., et al. Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis. J Clin Endocrinol Metab 2008, 93:1758-1766.
4. Yaker S., Rosen S.J., Beamer W.G., et al. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002, 110:771-781.
5. Dasu M.R., Devaraj S., Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007, 293:E337-E346.
6. Street M.E., Ziveri M.A., Spaggiari C., Viani I., et al. Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF binding protein system inducing reduced bioactivity if IGFs in cystic fibrosis. Eur J Endocrinol 2006, 154:47-52.
7. Moyer-Miler L.J., Slater H., Jordan K.C., et al. IGF-I and IGF-binding protein and bone mass, geometry, and strength: relation to metabolic control in adolescents girls with type 1 diabetes. J Bone Min Res 2008, 23:1884-1891.
8. Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity. Britch Children, 1965. Part II. Arch Dis Child 1966, 41:612-634.
9. Weintrob N., Amitay I., Lilos P., Shalitin S., Lazar L., Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 2007, 21(1):13-19.
10. Young M.J., Boulton A.J., Macleod A.F., Williams D.R., Sonksen P.H. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150-154.
11. Wilkinson C.P., Ferris F.L., Klein R.E., Lee P.P., Agardh C.D., Davis M., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.
12. Tabaei B., Al-Kassab A., Zawaski C., Herman W. Does microalbuminuria predict diabetic nephropathy?. Diabetic Care 2001, 24(9):1560-1566.
13. Warner J.T., Cowan F.J., Dunstan F.D., Evans W.D., Webb D.K., Gregory J.W. Measured and predicted bone mineral content in healthy boys and girls aged 6-18years: adjustment for body size and puberty. Acta Paediatr 1998, 87:244-249.
14. Dogan Y., Akarsu S., Ustundag B., Yilmaz E., Gurgoze M.K. Serum IL-1beta, IL-2 and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 2006, 59206:1-6.
15. Cavallo M.G., Pozzilli P., Bird C., Wadhwa M., Meager A., Visalli N., et al. Cytokines in sera from insulin dependent diabetic patients at diagnosis. Clin Exp Immunol 1991, 86:256-259.
16. Esposito K., Nappo F., Marfella R., Giugliano G., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation 2002, 106:2067-2072.
17. Schmidt A.M., Hori O., Cao R., et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996, 45(Suppl. 3):S77-S80.
18. Targher G., Bertolini L., Zoppini G., Zenari L., Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005, 22:999-1004.
19. Devaraj S., Glaser N., Griffen S., Wang-Polagruto J., Miguelino E., Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006, 55:774-779.
20. Erbaĝci A.B., Tarakçioĝlu M., Coskun Y., Sivasli E., Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001, 34:645-650.
21. Lo H.C., Lin S.C., Wang Y.M., et al. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clin Biochem 2004, 37(8):666-672.
22. Colson A., Le Cam A., Maiter D., Edery M., Thissen J.P. Potentiation of growth hormone-induced liver suppressors of cytokine signaling messenger ribonucleic acid by cytokines. Endocrinology 2000, 141:3687-3695.
23. Thissen J.P., Verniers J. Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997, 138:1078-1084.
24. De Benedetti F., Meazza C., Oliveri M., Pignatti P., Vivarelli M., Alonzi T., et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001, 142(11):4818-4826.
25. Wedrychowicz A., Dziatkowiak H., Sztefko K., Wedrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004, 112(8):435-439.
26. De Benedetti F., Meazza C., Martini A. Role of interleukin-6 in growth failure: an animal model. Horm Res 2002, 58(Suppl. 1):24-27.
27. Heap J., Murray M.A., Miller S.C., Jalili T., Moyer-Mileur L.J. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr 2004, 144:56-62.
28. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta analysis. Osteoporos Int 2007, 18:427-444.
29. De Schepper J., Smitz J., Rosseneu S., Bollen P., Louis O. Lumbar spine bone mineral density in diabetic children with recent onset. Horm Res 1998, 50:193-196.
30. Liu E.Y., Wactawski-Wende J., Donahue R.P., Dmochowski J., Hovey K.M., Quattrin T. Does low bone mineral density start in post-teenage years in women with type 1 diabetes?. Diabetes Care 2003, 26:2365-2369.
31. McCabe L., Zhang J., Raehtz S. Understanding the skeletal pathology of type 1 and 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 2011, 21(2):187-202.
32. McCabe L.R. Understanding the pathology and mechanisms of type 1 diabetic bone loss. J Cell Biochem 2007, 102:1343-1357.
33. Hock J.M., Krishnan V., Onyia J.E., Bidwell J.P., et al. Osteoblast apoptosis and bone turn over. J Bone Miner Res 2001, 16:975-984.
34. Manolagas S.C., Jilka R.L. Bone marrow, cytokines and bone remodeling. N Engl J Med 1995, 332:305-311.
35. Roberto P. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996, 11:1043-1051.
36. Chlebna-Sokol, Rusinska A. Serum insulin-like growth factor 1, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis. Endocrine Regul 2001, 35:201-208.
37. Mastrandrea L.D., Hovey K.M., Wactawski-Wende J., et al. Young women with type 1 diabetes have lower bone mineral density that persist over time. Diabetes Care 2008, 319:1729-1735.
38. Kemink S.A., Hermus A.R., Swinkels L.M., et al. Osteopenia in insulin-dependent diabetes mellitus: prevalence and aspects of pathophysiology. J Endocrinol Invest 2000, 23:295-303.
39. Jassal S.K., Muhlen D., Barrett-Connor Z., et al. Serum insulin-like growth factor binding-1 levels and bone mineral density in older adults: the Rancho Bernardo study. Osteoporos Int 2005, 16:1948-1954.
40. Landin-Wilhelmsen K., Wilhelmsen L., Bengtsson B.A. Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors. Clin Endocrinol (Oxf) 1999, 51(4):387-394.
41. Pascual J., Argente J., Lopez M.B., Muñoz M.B., Martinez G., Vazquez M.A., et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 1998, 62:31-35.
42. Heilman K., Zilmer M., Zilmer K., Tillmann V. Lower bone mineral density in children with type 1 diabetes is associated with poor glycemic control and higher serum ICAM-1 and urinary isoprostane levels. J Bone Miner Metab 2009, 27(5):598-604.
43. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000, 23:644-649.
44. Konukoglu D., Hatemi H., Bayer H., Bagriacik N. Relationship between serum concentrations of interleukin-6 and tumor necrosis factor alpha in female Turkish subjects with normal and impaired glucose tolerance. Horm Metab Res 2006, 38:34-37.
45. McCarty M.F., et al. Interleukin-6a ascentral mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol, and pntoxifylline. Med Hypothes 1999, 52:465-477.
46. Nishimura F., Takahash K., Kurihara M., Takashiba S., Murayama Y. Peri-dontal disease as a complication of diabetes mellitus. Ann Peridontol 1998, 3:20-29.
47. Kado S., Nagase T., Nagata N., et al. Circulating levels of interleukine-6, its soluble receptor and interleukine-6/ interleukine-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 1999, 36:67-72.
48. Van Sickle B.J., Simmons J., Hall R., Raines M., Ness K., Spagnoli A. Increased circulating IL-8 is associated with reduced IGF-1 and related to poor metabolic control in adolescents with type 1 diabetes mellitus. Cytokine 2009, 48(3):290-294.
49. Espallargues M., Sampietro-Colom L., Estrada M.D., Solà M., del Rio L., Setoain J., et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systemic review of the literature. Osteoporos Int 2001, 12(10):811-822.
50. Shapses S.A., Riedt C.S. Bone, body weight, and weight reduction: what are the concerns?. J Nut 2006, 136(6):1453-1456.
51. Rohrer T., Stierkorb E., Heger S., Karges B., Raile K., Schwab K.O., et al. Diabetes-patienten-verlaufsdaten (DPV) initiative. delayed pubertal onset and development in German children and adolescents with type 1 diabetes: cross-sectional analysis of recent data from the DPV diabetes documentation and quality management system. Eur J Endocrinol 2007, 157:647-653.
52. Peraldi P., Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998, 182(1-2):169-175.
53. Schmidt M.I., Duncan B.B., Sharrett A.R., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353(9165):1649-1652.
54. DCCT Research Group The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995, 122:561-568.
55. Dyck P.J., Davies J.L., Wilson D.M., Service F.J., Melton L.J., O'Brien P.C. Risk factors for severity of diabetic polyneuropathy. Diabetes Care 1999, 22:1479-1486.
56. Matsuda M., Kawasai F., Inoue H., Kanda Y. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract 2004, 66(Suppl. 1):S121-S123.
57. Herder C., Lankisch M., Ziegler D., Rathmann W., Koenig W., Illig T., et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009, 32(4):680-682.
58. Kauffmann D., van Meurs J., Mertens D., Peperkamp E., Master C., Gerritse M. Cytokine invitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1994, 35:900-906.
59. Balk well F.R., Burke F. The cytokine network. Immunol Today 1989, 10:299-304.
60. De Vos A.F., Van Haren M.A., Verhagen C., Hoekzema R., Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994, 35:1100-1106.
61. Elner S.G., Strieter R., Bian Z.M., Kunkel S., Mokhtarzaden L., et al. Interferon-induced protein 10 and interleukin 8: C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998, 116:1597-1601.
62. Temaru R., Urakaze M., Satou A., Yamazaki K., Nakamura N., Kobayashi M. High glucose enhances the gene expression of interleukin-8 in human endothelial cells but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia 1997, 40:610-613.
63. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
64. Hasegawa G., Nakano K., Sawada M., et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991, 40:1007-1012.
65. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I. MRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
66. Sugimoto H., Shikata K., Wada J., et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the over expression of tumour necrosis factor-alpha and inducible oxide synthase in diabetic rat glomerli. Diabetologia 1999, 42:878-886.
67. Soltesz G., Patterson C.C., Dahlquist G. EURODIAB Study Group Worldwide childhood type 1 diabetes incidence - what can we learn from epidemiology?. Pediatr Diabetes 2007, 8(Suppl. 6):6-14.
68. Pound N., Sturrock N.D.C., Jeffcoate W.J. Age related changes in glycated haemoglobin in patients with insulin-dependent diabetes mellitus. Diabet Med 1996, 13:510-513.
69. Nordly S., Jorgensen T., Andreasen A.H., Hermann N., Mortensen H.B. Quality of diabetes management in children and adolescents in Denmark. Diabet Med 2003, 20:568-574.
70. Kelly S.D., Howe C.J., Hendler J.P., Lipman T.H. Disordered eating behaviors in youth with type 1 diabetes. Diabetes Educ 2005, 31:572-583.
71. Shoff S.M., Klein R., Moss S.E., Klein B.E., Cruickshanks K.J. Weight change and glycemic control in a population-based sample of adults with older-onset diabetes. J Gerontol A Biol Sci Med Sci 1998, 53(1):M27-M32.